SCHEMBL4403713

SCHEMBL4403713

CCN(CC)Cc1ccc(C(=O)Nc2ccc(C)c(Nc3nccc(-c4cccnc4)n3)c2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 15/20 0.79
ABL1 P00519 11/20 0.79
KIT P10721 8/20 0.79
BCR P11274 8/20 0.77
PDGFRB P09619 6/20 0.77
EGFR P00533 2/20 0.75
PRKCA P17252 1/20 0.75
DDR1 Q08345 2/20 0.73
KDR P35968 2/20 0.71
ABL2 P42684 2/20 0.70
PLK4 O00444 1/20 0.70
DDX3X O00571 1/20 0.70
GAK O14976 1/20 0.70
SLC22A2 O15244 1/20 0.70
MAPK13 O15264 1/20 0.70
CA12 O43570 1/20 0.70
SLC22A3 O75751 1/20 0.70
ABCB11 O95342 1/20 0.70
CA1 P00915 1/20 0.70
CA2 P00918 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29552044 0.92 PDGFRA (0.77) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251012 0.92 PDGFRA (0.77) PDGFRAABL1KITBCRPDGFRB
SCHEMBL4399624 0.92 ABL1 (0.82) PDGFRAABL1KITBCRPDGFRB
SCHEMBL805395 0.91 PDGFRA (0.85) PDGFRAABL1KITBCRPDGFRB
SCHEMBL21248036 0.90 PDGFRA (0.84) PDGFRAABL1KITBCRPDGFRB
SCHEMBL27804782 0.89 PDGFRA (0.85) PDGFRAABL1KITBCRPDGFRB
SCHEMBL3568536 0.89 ABL1 (0.73) PDGFRAABL1KITBCRPDGFRB
SCHEMBL27962634 0.88 PDGFRA (0.81) PDGFRAABL1KITBCRPDGFRB
SCHEMBL29628979 0.88 PDGFRA (1.00) PDGFRAABL1KITBCRPDGFRB
SCHEMBL14292529 0.88 PDGFRA (0.84) PDGFRAABL1KITBCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102453-A1 N-phenyl-2-pyrimidine-amine derivatives NOVARTIS AG (CH) 2004-05-27 US claimed
EP-1322634-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES Novartis AG (CH) 2003-07-02 EP claimed
WO-2002022597-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES NOVARTIS AG (CH) 2002-03-21 WO claimed
EP-1322634-B1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES NOVARTIS AG (CH) 2009-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102453-A1 N-phenyl-2-pyrimidine-amine derivatives NUDT1, PNP, TYMP PDGFRA 77/4885ABL1 68/4885KIT 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.